Bristol, Ultima Genomics, and Cityblock Health, the Most Innovative Companies in Healthcare in 2023

Health is included among the most innovative companies in the world. Bristol Myers-Squibb, Ultima Genomics, and Cityblock Health are consolidated as the most innovative companies in the healthcare sector in 2023, according to the ranking prepared by Fast Company, which reveals the fifty most outstanding corporations in this field worldwide.

The American pharmaceutical company Bristol Myers-Squibb is ranked 18th overall, surpassing multinationals from other sectors such as the Walt Disney Company or Valve. The other two specialist healthcare companies, Ultima Genomics and Cityblock Health rank within the Top 40.

Bristol Myers-Squibb is one of the oldest laboratories in the world, founded in 1887. The pharmaceutical company’s headquarters are in New York. The group is focused on oncology treatments, immunotherapies, cardiology, and fibrosis.

The pharmaceutical company had a great 2022 with the approval of three new drugs by the US Food and Drug Administration (FDA). The drugs are Opdualag, a treatment for melanoma advances; Camzyos, a cardiac drug, and Sotyktu, a new oral drug for psoriasis. Bristol Myers-Squibb is an outstanding company because it currently has an investment plan of 150 million dollars over five years, an outlay that will serve to address health disparities and increase clinical trials.

Read more about the most innovative companies in healthcare in 2023, and find the most important business news of the day with the Born2Invest mobile app.

Bristol Myers-Squibb has an investment plan of $150 million over five years

The second most innovative company in the health sector is Cityblock Health, an American company that provides healthcare services to low-income people. The company combines primary care, behavioral health, and chronic disease management service.

With an office in Brooklyn, the operator also offers 70,000 jobs for health professionals who offer their services for free through partnerships with insurers. The company had a turnover of 5.7 billion dollars in 2022. Cityblock Health is in position 29 in the global ranking.

Ultima Genomics, for its part, is an American laboratory specializing in DNA analysis. Last year, the company presented a sequencing platform that allows more DNA to be read in the same time and offers the possibility of sequencing human genomes for a hundred euros. In July 2022, Ultima Genomics signed an agreement with Regeneron, from which the two companies are preparing to create new tools for the analysis of new genomes. This operator is in position forty in the general ranking.

Beyond these companies, there are also others such as Scopio Labs, a laboratory that has developed an artificial intelligence (AI) platform to automate the analysis of peripheral blood smears. The machine can process more than forty samples in one hour.

In parallel, Scopio Labs is launching a platform to digitally scan and analyze bone marrow samples. In 2022, the company announced a partnership with Beckman Coulter, one of the world’s leading distributors of medical devices.

The global ranking is led by OpenAl, “for multiplying how artificial intelligence will change everything”. OpenAI was among the first to step foot in generative artificial intelligence with tools like ChatGPT and Dall-E. Designed for research purposes, ChatGPT has already reached one hundred million users and Microsoft, the American giant, has announced that it will integrate OpenAI tools into its products and contribute $10 billion to the company.

__

(Featured image by  jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.